GlassScriptPhysician profile
Ira L Flax
NPI 1366419954
$1,241.62
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $704 · 2020: $267 · 2021: $257 · 2022: $13.82.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $276.10 | 2019-2022 | |
| Allergan, INC. | $184.71 | 2019-2020 | |
| Braintree Laboratories, INC. | $126.04 | 2019 | |
| Pfizer INC. | $115.40 | 2019-2021 | |
| Intercept Pharmaceuticals, INC. | $99.71 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.03 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $68.04 | 2019-2021 | |
| Gilead Sciences, INC. | $56.88 | 2019 | |
| Qol Medical, LLC | $53.77 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $40.85 | 2019 | |
| Janssen Biotech, INC. | $35.51 | 2019-2020 | |
| Boston Scientific Corporation | $19.19 | 2019 | |
| Dynavax Technologies Corporation | $18.37 | 2019 | |
| Amgen INC. | $17.85 | 2019 | |
| Ironwood Pharmaceuticals, INC | $16.48 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $13.29 | 2019 | |
| Intra-Sana Laboratories | $9.40 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ira Flax listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.